What’s New in CLL?
- ASH 2020: Dr. Paul Barr on Combining Rituximab with BTK Inhibitors for Treatment of CLL
- What’s Safe and What’s Not So Safe to Do During the COVID-19 Pandemic? CDC and CLL Society Offer Guidance
- ASH 2020: Dr. Paul Barr’s Update on the Combination of Umbralisib, Ublituximab, and Venetoclax for Treatment of CLL
- Help CLL Society Gain a Better Understanding of What Areas of CLL Research Are Most Important to Those We Serve
Get The Best Care for Your Chronic Lymphocytic Leukemia (CLL)
The CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on
patient education, support and research. Dedicated to addressing the unmet needs of the (CLL) chronic lymphocytic leukemia and
related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials,
support and build patient networks, engage in research and educate providers and patients.
CLL Society Expert Access™
Access to a CLL expert is critical to ensure receiving the best possible care and has proven to improve survival. In partnership with Verastem Oncology (Expert Access Founding Supporter), Genentech, and InfiniteMD, the CLL Society is proud to offer this free second opinion program for CLL patients.
We Are in this Together
-
Pingback: ABT-199 (venetoclax) in Combination Treatment for CLL